Yuhan Corporation

Hyosung Corporation

Hyun-Soo Kim

Ik-Hyun Kwon

Young-Gyo Choi

Young-Joon Park

Byung-Jun Song

Woo-Sung Kim

Hang-Bum Jo

Disclosed herein is a process of producing high purity and high yield dimethylnaphthalene by dehydrogenating a dimethyltetralin isomer using a metal catalyst for dehydrogenation. The metal catalyst contains a carrier selected from alumina (AlO), silica (SiO), a silica-alumina mixture and zeolite. The metal catalyst also contains 0.05 to 2.5% by weight of platinum (Pt), 0.1 to 3.0% by weight of tin (Sn) or indium (In), 0.5 to 15.0% by weight of at least one selected from the group consisting of potassium (K), magnesium (Mg) and cesium (Cs), 0.3 to 3.0% by weight of chlorine, and 0.01 to 3.0 % by weight of zinc (Zn) or gallium (Ga) as active components based on an element weight of the final catalyst.

Dehydrogenation process of dimethylnaphthalene using metal catalyst

A pharmaceutical capsule composition for oral administration exhibiting controllable, satisfactory release profiles of both loratadine and pseudoephedrine or its salts, which comprises: (a) a plurality of rapid-release pellets (pellets A), each pellet containing (i) a therapeutically effective amount of loratadine, (ii) pseudoephedrine or a pharmaceutically acceptable salt thereof, and (iii) one or more pharmaceutically acceptable excipients; and (b) a plurality of extended-release pellets (pellets B), each pellet containing (i) pseudoephedrine or a pharmaceutically acceptable salt thereof and (ii) one or more pharmaceutically acceptable excipients, which are coated with a water-insoluble polymer in an amount ranging from 2 to 30 wt % and a wet-blocking agent selected from the group consisting of magnesium stearate, talc, fatty acid ester and a mixture thereof in an amount ranging from 2 to 30 wt %, based on the total weight of pellets B.

Pharmaceutical capsule compositions containing loratadine and psuedoephedrine

Growing community of inventors

Kyonggi-do, South Korea

Hyun-Soo Kim